UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): May 25, 2006
CELGENE CORPORATION
-------------------
(Exact name of registrant as specified in its charter)
Delaware 0-16132 22-2711928
---------------------------- ------------------------ -------------------
(State or other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
86 Morris Avenue, Summit, New Jersey 07901
------------------------------------------------------ ---------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (908) 673-9000
------------------------------------------------------------------
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
|_| Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
ITEM 8.01 OTHER EVENTS
On May 25, 2006, Celgene Corporation announced that the U.S. Food and Drug
Administration has granted accelerated approval to its Supplemental New Drug
Application for THALOMID(R) (thalidomide) in combination with dexamethasone for
the treatment of newly diagnosed multiple myeloma. Attached hereto and
incorporated by refernce as Exhibit 99.1 is the press release announcing such
information.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
(c) Exhibit 99.1 - Press Release Dated May 25, 2006
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
CELGENE CORPORATION
Date: May 26, 2006 By: /s/ Robert J. Hugin
---------------------- --------------------------
Name: Robert J. Hugin
Title: President and
Chief Operating Officer